Market Insight - Influenza: the avoidable killer
This article was originally published in Scrip
Despite the long-standing availability of vaccines, seasonal influenza still accounts for 300,000-500,000 deaths annually worldwide,1 and creates considerable economic strain and burden on healthcare providers, during the intense four- to five-month influenza season each year. Not only do challenges remain in the reduction of morbidity and mortality caused by seasonal influenza, a real threat of pandemic influenza is today a genuine and increasing concern. The current environment surrounding influenza is therefore one of significant investment, regulatory and policy change, and global co-operation efforts in an attempt to minimise the burden of seasonal influenza and maximise preparedness for a pandemic.
You may also be interested in...
One year after acquiring Piramal's Domestic Formulations business in a deal that made it India's largest pharmaceutical player, Abbott remains confident about its growth prospects in India, where it hopes to be generating $2.5 billion in sales by 2020. But facing fierce competition from domestic firms, Abbott isn't about to get complacent, Michael Warmuth, senior VP of the company's Established Products Division, tells Pete Chan. This article is part of the 2011 Scrip Asia 100.
Asia life science-focused VC firms*
Roche is overhauling its cost structure to produce a leaner organisation better equipped to focus on the business of pharmaceutical innovation. It is also investing heavily in China, turning its Shanghai operations into a centre for everything from commercial manufacturing and research to partnering, licensing and strategic planning. Pascal Soriot, chief operating officer of Roche Pharmaceuticals, speaks to Pete Chan in an exclusive interview.